Company intelligence / Profile preview
Acepodia
Grand Cayman, Grand Cayman, Cayman Islandsacepodia.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Acepodia has multiple programs in clinical development. ACE1831 (targeting CD20) is in Phase 1 for non-Hodgkin's lymphoma and is being evaluated for IgG4-related disease. ACE2016 (targeting EGFR) is in Phase 1 for solid tumors. ACE1702 (targeting HER2) has shown safety and tolerability in Phase 1 for HER2-positive tumors.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Cell therapiesAntibody-Cell ConjugatesNatural Killer Cell Therapiesγ-δT cell therapiesAntibody-Dual-Drugs Conjugation (AD2C)
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
Pfizer Inc. (strategic clinical collaboration for autoimmune diseases)
Beyond the preview
Go deeper on Acepodia.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Acepodia.